Trevi Therapeutics price target raised to $12 from $8 at Stifel

Stifel analyst Annabel Samimy raised the firm’s price target on Trevi Therapeutics (TRVI) to $12 from $8 and keeps a Buy rating on the shares with the read-out of Trevi’s Phase 2a RIVER trial of Haduvio in refractory chronic cough “rapidly approaching.” While Haduvio has potential to serve as the singular product for one of the most debilitating symptoms of idiopathic pulmonary fibrosis chronic cough, RCC “could offer its second blockbuster opportunity” and increase strategic interest, the analyst tells investors.